<main lang="en" class="detailed-guide" role="main">
      
<div class="govuk-grid-row">
  <div class="govuk-grid-column-two-thirds">
    <div class="gem-c-title govuk-!-margin-top-8 govuk-!-margin-bottom-8">
    <span class="govuk-caption-xl gem-c-title__context">
      Guidance
    </span>
  <h1 class="gem-c-title__text gem-c-title__text--long">
    Unfettered Access Procedure for marketing authorisations approved in Northern Ireland
  </h1>
</div>
  </div>
  
  <div class="govuk-grid-column-two-thirds">
    
  <p class="gem-c-lead-paragraph">How to apply for the Unfettered Access Procedure (UAP). </p>

  </div>
</div>

<div class="govuk-grid-row">
  <div class="metadata-logo-wrapper">
    <div class="govuk-grid-column-two-thirds metadata-column">
        <div lang="en" class="app-c-publisher-metadata">
    <div lang="en" class="app-c-published-dates ">
    Published 4 January 2021
    <br>Last updated 23 February 2021
      — <a class="app-c-published-dates__history-link govuk-link" href="#history">see all updates</a>
</div>

      <div class="app-c-publisher-metadata__other">
        <dl data-module="track-click">
            <dt class="app-c-publisher-metadata__term">
              From:
            </dt>
            <dd class="app-c-publisher-metadata__definition" data-module="gem-toggle">
                <span class="app-c-publisher-metadata__definition-sentence">
                  <a href="/government/organisations/medicines-and-healthcare-products-regulatory-agency" class="govuk-link">Medicines and Healthcare products Regulatory Agency</a>
                </span>
            </dd>
        </dl>
      </div>
  </div>

    </div>
    <div class="govuk-grid-column-one-third">
    </div>
  </div>
</div>





<div class="govuk-grid-row">
  <div class="govuk-grid-column-two-thirds">
    

      <div class="app-c-contents-list-with-body" data-module="sticky-element-container">
      <div class="responsive-bottom-margin">
          <nav role="navigation" class="gem-c-contents-list  gem-c-contents-list--no-underline " aria-label="Contents" data-module="track-click">
    <h2 class="gem-c-contents-list__title">
      Contents
</h2>
    <ol class="gem-c-contents-list__list">
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-label="#how-to-apply" href="#how-to-apply" data-track-action="content_item 1" data-track-category="contentsClicked" data-track-options="{&quot;dimension29&quot;:&quot;How to apply&quot;}">How to apply</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a data-track-category="contentsClicked" data-track-label="#fees" href="#fees" data-track-action="content_item 2" class="gem-c-contents-list__link govuk-link " data-track-options="{&quot;dimension29&quot;:&quot;Fees&quot;}">Fees</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a data-track-category="contentsClicked" data-track-label="#assessment-procedure" href="#assessment-procedure" class="gem-c-contents-list__link govuk-link " data-track-action="content_item 3" data-track-options="{&quot;dimension29&quot;:&quot;Assessment procedure&quot;}">Assessment procedure</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a data-track-action="content_item 4" data-track-options="{&quot;dimension29&quot;:&quot;If Major Objections are raised&quot;}" href="#if-major-objections-are-raised" class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-label="#if-major-objections-are-raised">If Major Objections are raised</a>

        </li>
    </ol>
</nav>
      </div>
    
      
<div class="gem-c-print-link govuk-!-margin-top-0 govuk-!-margin-bottom-6">
    <button class="govuk-link gem-c-print-link__button" data-module="print-link">Print this page</button>
</div>

      
<div class="gem-c-govspeak govuk-govspeak " data-module="govspeak">
    
        <div class="govspeak">
<p>Marketing Authorisation Holders (MAHs) may seek recognition in Great Britain of a Marketing Authorisation (<abbr title="Marketing Authorisation">MA</abbr>) approved in Northern Ireland.</p>

<p>This route - the Unfettered Access Procedure (<abbr title="Unfettered Access Procedure">UAP</abbr>) - is available to <abbr title="Marketing Authorisations">MAs</abbr> approved in Northern Ireland via European procedures (centralised, mutual recognition or decentralised procedures) or via the Northern Ireland National route.</p>

<p>Refer to <a href="https://www.gov.uk/guidance/moving-qualifying-goods-from-northern-ireland-to-the-rest-of-the-uk" class="govuk-link">guidance on conditions for eligibility of unfettered access</a>, and <a rel="external" href="https://www.legislation.gov.uk/uksi/2020/1454/regulation/3/made" class="govuk-link">definitions of qualifying Northern Ireland goods</a>.</p>

<p>The intention is that acceptable Marketing Authorisation Applications (<abbr title="Marketing Authorisation Applications">MAAs</abbr>) should be recognised by the MHRA for Great Britain (England, Scotland and Wales) within 67 days of MAA validation, unless Major Objections are identified.</p>

<h2>How to apply</h2>

<p>If the company does not have a 5-digit company number, to allow registration on the MHRA Submissions Portal, then this should be requested from <a class="govuk-link" href="mailto:Reference.Data@mhra.gov.uk">Reference.Data@mhra.gov.uk</a>. A PLGB number can then be obtained through <a href="https://www.gov.uk/guidance/register-to-make-submissions-to-the-mhra" class="govuk-link">MHRA Submissions</a> or by emailing <a href="mailto:PLNumberAllocation@mhra.gov.uk" class="govuk-link">PLNumberAllocation@mhra.gov.uk</a> prior to submission.</p>

<p>The entire dossier as approved for marketing in Northern Ireland, including the full company responses to the Committee for Medicinal Products for Human Use (CHMP)/Reference Member State (<abbr title="Reference Member State">RMS</abbr>)/Concerned Member State (<abbr title="Concerned Member States">CMS</abbr>) questions, should be submitted to the MHRA as one <a rel="external" class="govuk-link" href="http://esubmission.ema.europa.eu/ectd/">electronic Common Technical Document</a> sequence through <a class="govuk-link" href="https://www.gov.uk/guidance/register-to-make-submissions-to-the-mhra">MHRA Submissions</a>.</p>

<p>If the entire dossier has already been submitted to the MHRA as Northern Ireland, and no changes are required for the <abbr title="Unfettered Access Procedure">UAP</abbr> MAA dossier, the dossier need not be submitted for the <abbr title="Unfettered Access Procedure">UAP</abbr> MAA.</p>

<p>The Working Documents Folder should include:</p>

<ul>
  <li>all iterations of the CHMP/<abbr title="Reference Member State">RMS</abbr>/Northern Ireland assessment reports and End of Procedure documents for the initial MAA and subsequent variations,</li>
  <li>the proposed product information in Microsoft Word format,</li>
  <li>the <abbr title="Marketing Authorisation">MA</abbr> grant letter as approved in Northern Ireland.</li>
</ul>

<h3>Orphan designation</h3>
<p>If an <a class="govuk-link" href="https://www.gov.uk/guidance/orphan-medicinal-products-in-great-britain">orphan designation</a> is sought, the Great Britain Orphan Drug Designation Application Form should be submitted in module 1.2 of the <abbr title="electronic Common Technical Document">eCTD</abbr>. Email <a href="mailto:IPUenquiries@mhra.gov.uk" class="govuk-link">IPUenquiries@mhra.gov.uk</a> if you have any questions about submitting your application.</p>

<h3>Paediatric requirements</h3>
<p>For submissions which will trigger paediatric requirements, applicants should ensure the latest European Union and/or Great Britain-<abbr title="Paediatric Investigation Plan">PIP</abbr>/waiver opinion/decision or class waiver decision is included in the dossier.</p>

<p>If the application has been subject to a European Union or Great Britain compliance check the outcome documents should be included in the dossier.</p>

<p>The applicant should also indicate any parallel, ongoing or previous applications containing paediatric data relevant for the full <abbr title="Paediatric Investigation Plan">PIP</abbr> compliance verification (if applicable). An overview table of the <abbr title="Paediatric Investigation Plan">PIP</abbr> results, indicating in which application(s) they were/are going to be submitted, status of the application(s), as well as their location in the present application must be included.</p>

<h3>Cover letter</h3>

<p>The cover letter accompanying the application should:</p>

<ul>
  <li>Clearly state the regulatory route as <abbr title="Unfettered Access Procedure">UAP</abbr> to ensure appropriate handling, including the relevant procedure number for the Northern Ireland <abbr title="Marketing Authorisation">MA</abbr>
</li>
  <li>Include a declaration of conformity of the Great Britain application with the dossier approved for marketing in Northern Ireland, including approved variations</li>
  <li>Include a declaration that all iterations of the CHMP/<abbr title="Reference Member State">RMS</abbr>/Northern Ireland assessment reports and End of Procedure documents have been submitted. These assessment reports should also be listed</li>
  <li>Include a declaration that the proposed product information is identical to that approved in the Northern Ireland <abbr title="Marketing Authorisation">MA</abbr>, and that the product information in Microsoft Word format has been included with the submission</li>
  <li>If an <a class="govuk-link" href="https://www.gov.uk/guidance/orphan-medicinal-products-in-great-britain">orphan designation</a> is sought, confirm that the Great Britain Orphan Drug Designation Application Form has been submitted in module 1.2 of the <abbr title="electronic Common Technical Document">eCTD</abbr>
</li>
  <li>Indicate whether paediatric requirements will be triggered, and if so, that the paediatric information is included in the dossier. The applicant should indicate if this application has been subject to a European Union or Great Britain-<abbr title="Paediatric Investigation Plan">PIP</abbr> compliance check and confirm whether any <abbr title="Paediatric Investigation Plan">PIP</abbr> studies were due to initiate or complete since compliance verification</li>
  <li>If the procedure includes an <abbr title="Active Substance Master File">ASMF</abbr>, include a declaration that the <abbr title="Active Substance Master File">ASMF</abbr> Holder has submitted the Applicant’s and Restricted Parts of the <abbr title="Active Substance Master File">ASMF</abbr>, including approved variations and all iterations of the assessment reports on the Applicant’s and Restricted Parts</li>
  <li>Include a declaration that the proposed Risk Management Plan (<abbr title="Risk Management Plan">RMP</abbr>) is identical to <abbr title="Risk Management Plan">RMP</abbr> in Northern Ireland/European Union.</li>
  <li>State any conditions associated with the Marketing Authorisation</li>
</ul>

<p>If it is found during the assessment phase that the dossier is incomplete or assessment reports have been omitted, this will be raised as a Point for Clarification, and may cause a delay to the 67-day timetable.</p>

<h2>Fees</h2>

<p>The submission will <a href="https://www.gov.uk/government/publications/mhra-fees" class="govuk-link">attract a fee</a>.</p>

<h2>Assessment procedure</h2>

<p>All applications will be assessed to ensure they comply with UK regulatory requirements, including those related to:</p>

<ul>
  <li>Great Britain <a class="govuk-link" href="https://www.gov.uk/guidance/reference-medicinal-products-rmps">Reference Medicinal Products</a>
</li>
  <li>product name</li>
  <li>labelling</li>
  <li>patient information legibility</li>
  <li>supply status</li>
  <li>controlled drug scheduling where necessary</li>
  <li>paediatric and orphan medicine requirements, where relevant</li>
</ul>

<p>The first round of assessment should be completed by Day 42. It is anticipated that the vast majority of Great Britain <abbr title="Marketing Authorisations">MAs</abbr> will be approved at this point.</p>

<p>Any issues identified during assessment will be communicated, and should be resolvable within the 67-day timetable without clock-stop.</p>

<h2>If Major Objections are raised</h2>

<p>If Major Objections are identified or substantial amendments to the product information are necessary, the timetable will move to the standard National Procedure timetable. It is anticipated that this will be necessary only on rare occasions.</p>

</div>

</div>

      <div class="responsive-bottom-margin">
        <div data-module="toggle" class="app-c-published-dates app-c-published-dates--history" lang="en">
    Published 4 January 2021
    <br>Last updated 23 February 2021
      <a class="app-c-published-dates__toggle govuk-link" data-toggled-text="-&nbsp;hide all updates" data-expanded="false" href="#full-history" data-controls="full-history">+&nbsp;show all updates</a>
      <div class="app-c-published-dates__change-history js-hidden">
        <ol>
            <li class="app-c-published-dates__change-item">
              <time datetime="2021-02-23T11:18:00.000+00:00" class="app-c-published-dates__change-date timestamp">23 February 2021</time>
              <p class="app-c-published-dates__change-note">Updated information around how to get a 5-digit company number, and added new links to conditions for eligibility of unfettered access, and definitions of qualifying Northern Ireland goods.</p>
            </li>
            <li class="app-c-published-dates__change-item">
              <time class="app-c-published-dates__change-date timestamp" datetime="2021-01-04T14:30:00.000+00:00">4 January 2021</time>
              <p class="app-c-published-dates__change-note">First published.</p>
            </li>
        </ol>
      </div>
</div>

      </div>

      <div class="app-c-contents-list-with-body__link-wrapper" data-sticky-element="">
        <div class="app-c-contents-list-with-body__link-container">
          <a class="govuk-link app-c-back-to-top dont-print" href="#contents">
    <svg height="17" viewBox="0 0 13 17" class="app-c-back-to-top__icon" xmlns="http://www.w3.org/2000/svg" width="13">
      <path fill="currentColor" d="M6.5 0L0 6.5 1.4 8l4-4v12.7h2V4l4.3 4L13 6.4z"></path>
    </svg>
    Contents
</a>

        </div>
      </div>
  </div>
    
<div class="gem-c-print-link govuk-!-margin-top-0 govuk-!-margin-bottom-6">
    <button data-module="print-link" class="govuk-link gem-c-print-link__button">Print this page</button>
</div>
  </div>
  
<div class="govuk-grid-column-one-third">
  


</div>

</div>


  <div class="govuk-grid-row">
    <div class="govuk-grid-column-two-thirds">
        
  <div class="gem-c-contextual-footer">
    
  <div class="gem-c-related-navigation">





      <nav class="gem-c-related-navigation__nav-section" role="navigation" data-module="gem-toggle">

    <h2 data-track-count="footerRelatedItemSection" class="gem-c-related-navigation__sub-heading gem-c-related-navigation__sub-heading--footer">Explore the topic</h2>

  <ul data-module="track-click" class="gem-c-related-navigation__link-list">


        <li class="gem-c-related-navigation__link"><a data-track-options="{&quot;dimension28&quot;:&quot;1&quot;,&quot;dimension29&quot;:&quot;Marketing authorisations, variations and licensing guidance&quot;}" href="/topic/medicines-medical-devices-blood/marketing-authorisations-variations-licensing" data-track-category="relatedLinkClicked" class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--footer" data-track-label="/topic/medicines-medical-devices-blood/marketing-authorisations-variations-licensing" data-track-action="1.1 Explore the topic">Marketing authorisations, variations and licensing guidance</a></li>

  </ul>
</nav>

  </div>

  </div>


    </div>
  </div>


    </main>